164 related articles for article (PubMed ID: 10930700)
1. Disruption of sphingolipid metabolism in small intestines, liver and kidney of mice dosed subcutaneously with fumonisin B(1).
Enongene EN; Sharma RP; Bhandari N; Voss KA; Riley RT
Food Chem Toxicol; 2000 Sep; 38(9):793-9. PubMed ID: 10930700
[TBL] [Abstract][Full Text] [Related]
2. Early fumonisin B1 toxicity in relation to disrupted sphingolipid metabolism in male BALB/c mice.
Tsunoda M; Sharma RP; Riley RT
J Biochem Mol Toxicol; 1998; 12(5):281-9. PubMed ID: 9664234
[TBL] [Abstract][Full Text] [Related]
3. Persistence and reversibility of the elevation in free sphingoid bases induced by fumonisin inhibition of ceramide synthase.
Enongene EN; Sharma RP; Bhandari N; Miller JD; Meredith FI; Voss KA; Riley RT
Toxicol Sci; 2002 Jun; 67(2):173-81. PubMed ID: 12011476
[TBL] [Abstract][Full Text] [Related]
4. Dietary fumonisin B1 induces disruption of sphingolipid metabolism in Sprague-Dawley rats: a new mechanism of nephrotoxicity.
Riley RT; Hinton DM; Chamberlain WJ; Bacon CW; Wang E; Merrill AH; Voss KA
J Nutr; 1994 Apr; 124(4):594-603. PubMed ID: 8145083
[TBL] [Abstract][Full Text] [Related]
5. Disruption of sphingolipid metabolism and stimulation of DNA synthesis by fumonisin B1. A molecular mechanism for carcinogenesis associated with Fusarium moniliforme.
Schroeder JJ; Crane HM; Xia J; Liotta DC; Merrill AH
J Biol Chem; 1994 Feb; 269(5):3475-81. PubMed ID: 8106389
[TBL] [Abstract][Full Text] [Related]
6. Elevated sphingoid bases and complex sphingolipid depletion as contributing factors in fumonisin-induced cytotoxicity.
Yoo HS; Norred WP; Showker J; Riley RT
Toxicol Appl Pharmacol; 1996 Jun; 138(2):211-8. PubMed ID: 8658522
[TBL] [Abstract][Full Text] [Related]
7. Sphingolipid perturbations as mechanisms for fumonisin carcinogenesis.
Riley RT; Enongene E; Voss KA; Norred WP; Meredith FI; Sharma RP; Spitsbergen J; Williams DE; Carlson DB; Merrill AH
Environ Health Perspect; 2001 May; 109 Suppl 2(Suppl 2):301-8. PubMed ID: 11359699
[TBL] [Abstract][Full Text] [Related]
8. Ceramide synthase inhibition by fumonisin B1 treatment activates sphingolipid-metabolizing systems in mouse liver.
He Q; Suzuki H; Sharma N; Sharma RP
Toxicol Sci; 2006 Dec; 94(2):388-97. PubMed ID: 16960033
[TBL] [Abstract][Full Text] [Related]
9. Fumonisin B(1) induces apoptosis in LLC-PK(1) renal epithelial cells via a sphinganine- and calmodulin-dependent pathway.
Kim MS; Lee DY; Wang T; Schroeder JJ
Toxicol Appl Pharmacol; 2001 Oct; 176(2):118-26. PubMed ID: 11601888
[TBL] [Abstract][Full Text] [Related]
10. Alteration of tissue and serum sphinganine to sphingosine ratio: an early biomarker of exposure to fumonisin-containing feeds in pigs.
Riley RT; An NH; Showker JL; Yoo HS; Norred WP; Chamberlain WJ; Wang E; Merrill AH; Motelin G; Beasley VR
Toxicol Appl Pharmacol; 1993 Jan; 118(1):105-12. PubMed ID: 8430417
[TBL] [Abstract][Full Text] [Related]
11. Mycotoxin-induced elevation of free sphingoid bases in precision-cut rat liver slices: specificity of the response and structure-activity relationships.
Norred WP; Plattner RD; Dombrink-Kurtzman MA; Meredith FI; Riley RT
Toxicol Appl Pharmacol; 1997 Nov; 147(1):63-70. PubMed ID: 9356308
[TBL] [Abstract][Full Text] [Related]
12. Sphingoid bases and their phosphates: transient activation and delayed repression of protein kinase C isoforms and their possible involvement in fumonisin B1 cytotoxicity.
Gopee NV; Sharma RP
Toxicology; 2003 May; 187(2-3):239-50. PubMed ID: 12699912
[TBL] [Abstract][Full Text] [Related]
13. Evidence for disruption of sphingolipid metabolism as a contributing factor in the toxicity and carcinogenicity of fumonisins.
Riley RT; Wang E; Schroeder JJ; Smith ER; Plattner RD; Abbas H; Yoo HS; Merrill AH
Nat Toxins; 1996; 4(1):3-15. PubMed ID: 8680751
[TBL] [Abstract][Full Text] [Related]
14. Fumonisin-induced tumor necrosis factor-alpha expression in a porcine kidney cell line is independent of sphingoid base accumulation induced by ceramide synthase inhibition.
He Q; Riley RT; Sharma RP
Toxicol Appl Pharmacol; 2001 Jul; 174(1):69-77. PubMed ID: 11437650
[TBL] [Abstract][Full Text] [Related]
15. Fumonisin B1 consumption by rats causes reversible, dose-dependent increases in urinary sphinganine and sphingosine.
Wang E; Riley RT; Meredith FI; Merrill AH
J Nutr; 1999 Jan; 129(1):214-20. PubMed ID: 9915902
[TBL] [Abstract][Full Text] [Related]
16. Demonstration of in-situ apoptosis in mouse liver and kidney after short-term repeated exposure to fumonisin B1.
Sharma RP; Dugyala RR; Voss KA
J Comp Pathol; 1997 Nov; 117(4):371-81. PubMed ID: 9502273
[TBL] [Abstract][Full Text] [Related]
17. Fumonisin B(1) is hepatotoxic and nephrotoxic in milk-fed calves.
Mathur S; Constable PD; Eppley RM; Waggoner AL; Tumbleson ME; Haschek WM
Toxicol Sci; 2001 Apr; 60(2):385-96. PubMed ID: 11248152
[TBL] [Abstract][Full Text] [Related]
18. The effect of repeated gavage doses of fumonisin B1 on the sphinganine and sphingosine levels in vervet monkeys.
van der Westhuizen L; Shephard GS; van Schalkwyk DJ
Toxicon; 2001 Jul; 39(7):969-72. PubMed ID: 11223085
[TBL] [Abstract][Full Text] [Related]
19. Implications of apoptosis for toxicity, carcinogenicity, and risk assessment: fumonisin B(1) as an example.
Dragan YP; Bidlack WR; Cohen SM; Goldsworthy TL; Hard GC; Howard PC; Riley RT; Voss KA
Toxicol Sci; 2001 May; 61(1):6-17. PubMed ID: 11294969
[TBL] [Abstract][Full Text] [Related]
20. Toxicology and carcinogenesis studies of fumonisin B1 (cas no. 116355-83-0) in F344/N rats and B6C3F1 mice (feed studies).
Natl Toxicol Program Tech Rep Ser; 2001 Dec; (496):1-352. PubMed ID: 11852482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
